This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Background.
The production of neutralizing antibodies (NAB) may be associated with a reduction in clinical effectiveness of interferon beta 1b (IFN beta-1b). However, there are some NAB-positive patients who continue to do well, so the relationship between the clinical state and the NAB state is not constant. Approximately 90% of NAB-positive patients become so between six and 18 months of therapy. In the IFN beta-1b clinical trial, the data indicate that the relapse rate in NAB-positive patients after 18 months of high dose IFN beta-1b reverted to a level similar to placebo treated patients. NAB-negative patients on high dose IFN beta-1b continued to show progress, with a relapse rate of one half of both the NAB-positive patients and the placebo patients.
In order to help in clinical decision-making, a test for the detection …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Disputes & Debates: Rapid online correspondence
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.